Moteur de recherche d’entreprises européennes
Financement de l’UE (8 363 555 €) : CArtilage du nez pour le traitement de l’arthrose (ENCANTO) Hor01/01/2024 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
CArtilage du nez pour le traitement de l’arthrose (ENCANTO)
Knee osteoarthritis (OA) is one of the most common causes of pain and disability, affecting over 500 million people worldwide. The tremendous socio-economic burden caused by OA is expected to further increase due to rising life expectancy and obesity. Current therapeutic approaches are limited to pain management or knee arthroplasty, but no disease-modifying or regenerative treatment is available. ENCANTO will address this major unmet clinical need by clinically introducing a combined ATMP for the biological reconstruction of the degenerated joint facet in patellofemoral OA (PFOA). This tissue-engineered cartilage (N-TEC), based on autologous nasal chondrocytes and a collagen membrane, was previously successfully used for focal cartilage lesions. The central part of ENCANTO is an international, blinded, multicenter, prospective randomized controlled phase II trial to clinically assess the efficacy of N-TEC for the treatment of PFOA. Patients’ samples will be analyzed to retrospectively identify PFOA molecular endotypes and associated biomarker signatures with the most successful clinical outcome after N-TEC implantation, to predictively select responders to therapy. To achieve these aims ENCANTO brings together tissue engineers with practice in ATMPs, knee surgery and rehabilitation specialists, research institutes experienced in regulatory affairs, health economics and ATMP development, excellent scientists involved in the assessment of OA endotypes, and patients’ representatives. SMEs from the consortium will develop a road map towards commercial exploitation, including centralized marketing authorization. After demonstrating efficacy for PFOA, N-TEC will be considered for other forms of OA in different joints. ENCANTO will thus introduce the first disease-modifying therapy for cartilage degeneration, enable mobility and social gain for a large patient group and play a pivotal role in strengthening Europe's position in delivering regenerative medicine solutions.
| crossklinik AG | ? |
| EVANGELISCHES WALDKRANKENHAUS SPANDAU KRANKENHAUSBETRIEBS gGmbH | 347 300 € |
| Fondazione Policlinico Universitario Campus BIO Medico | 1 346 800 € |
| JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG | 347 300 € |
| KLINICKA BOLNICA SVETI DUH | 532 238 € |
| Medizinische Universitaet Wien | 445 778 € |
| Ortopadisches Spital Speising GmbH | 350 156 € |
| Ospedale Galeazzi S.p.A. | 0,00 € |
| OULUN YLIOPISTO | 442 848 € |
| PROMOVE-BIOTEC GmbH | 440 943 € |
| Szpital Specjalistyczny im. Stefana Zeromskiego Samodzielny Publiczny Zaklad Opieki Zdrowotnej w Krakowie | 271 963 € |
| Theracell Proigmenes Viotechnologikes Efarmoges Monoprosopi ΑΕ | 248 750 € |
| Universita Degli Studi Di Milano | 388 136 € |
| UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT | 1 880 920 € |
| UNIVERSITEIT MAASTRICHT | 506 875 € |
| Vastra Gotalandsregionen | 347 300 € |
| VIDEOREHA d.o.o. | 466 250 € |
https://cordis.europa.eu/project/id/101137315
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : crossklinik AG, Bâle, Suisse.
